Non-invasive assessment of muscle spasticity in children with cerebral palsy undergoing botulinum toxin treatment using near-infrared spectroscopy

Spasticity is a common and debilitating feature of cerebral palsy (CP), often treated with botulinum toxin A (BoNT-A). Standard assessments, such as the Modified Ashworth Scale (MAS), are subjective and prone to inter-rater variability. Near-infrared spectroscopy (NIRS) is a non-invasive method that measures muscle oxygenation and hemodynamics. In CP, spastic muscles exhibit impaired perfusion and abnormal oxygen consumption due to sustained contraction and elevated intramuscular pressure. Prior studies suggest that reducing spastic overactivity improves local tissue oxygenation, indicating that NIRS-derived metrics could objectively reflect spasticity severity and treatment response. To evaluate the feasibility of using NIRS as a biomarker for spasticity severity and treatment response in children with CP receiving BoNT-A and to assess the correlation between NIRS-derived tissue oxygenation index (TOI%) and MAS scores over time. In this prospective pilot study, eight children (aged 2–17 years) with CP undergoing BoNT-A treatment were assessed. Muscle oxygenation was recorded using a portable NIRS device at baseline, 2–4 weeks, 6–10 weeks, 3 months, and 6 months post-injection. Spasticity was measured concurrently using MAS. Temporal changes in TOI% and MAS were analyzed using repeated-measures ANOVA, and associations between the two were evaluated with Pearson correlation. TOI% increased significantly after injection, peaking at 6–10 weeks and 3 months (p < 0.001), then declined toward baseline by 6 months. MAS scores showed a similar trend, with reduced spasticity during peak effect. A moderate, significant negative correlation between TOI% and MAS (r = − 0.409, p < 0.05) indicated higher oxygenation was associated with lower spasticity. NIRS is a feasible, non-invasive tool for assessing muscle spasticity and monitoring BoNT-A response in children with CP. Its correlation with MAS supports physiological relevance and suggests NIRS may offer a more objective measure of spasticity. Larger studies are warranted to validate these findings and support clinical use.

Institutions

Publication Details

Journal
Journal of NeuroEngineering and Rehabilitation
Published
2025-12-22
DOI
https://doi.org/10.1186/s12984-025-01853-z
Primary Topic
Cerebral Palsy and Movement Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Non-invasive assessment of muscle spasticity in children with cerebral palsy undergoing botulinum toxin treatment using near-infrared spectroscopy

Journal of NeuroEngineering and Rehabilitation
Cerebral Palsy and Movement Disorders
article

Non-invasive assessment of muscle spasticity in children with cerebral palsy undergoing botulinum toxin treatment using near-infrared spectroscopy

article en

Abstract

Spasticity is a common and debilitating feature of cerebral palsy (CP), often treated with botulinum toxin A (BoNT-A). Standard assessments, such as the Modified Ashworth Scale (MAS), are subjective and prone to inter-rater variability. Near-infrared spectroscopy (NIRS) is a non-invasive method that measures muscle oxygenation and hemodynamics. In CP, spastic muscles exhibit impaired perfusion and abnormal oxygen consumption due to sustained contraction and elevated intramuscular pressure. Prior studies suggest that reducing spastic overactivity improves local tissue oxygenation, indicating that NIRS-derived metrics could objectively reflect spasticity severity and treatment response. To evaluate the feasibility of using NIRS as a biomarker for spasticity severity and treatment response in children with CP receiving BoNT-A and to assess the correlation between NIRS-derived tissue oxygenation index (TOI%) and MAS scores over time. In this prospective pilot study, eight children (aged 2–17 years) with CP undergoing BoNT-A treatment were assessed. Muscle oxygenation was recorded using a portable NIRS device at baseline, 2–4 weeks, 6–10 weeks, 3 months, and 6 months post-injection. Spasticity was measured concurrently using MAS. Temporal changes in TOI% and MAS were analyzed using repeated-measures ANOVA, and associations between the two were evaluated with Pearson correlation. TOI% increased significantly after injection, peaking at 6–10 weeks and 3 months (p < 0.001), then declined toward baseline by 6 months. MAS scores showed a similar trend, with reduced spasticity during peak effect. A moderate, significant negative correlation between TOI% and MAS (r = − 0.409, p < 0.05) indicated higher oxygenation was associated with lower spasticity. NIRS is a feasible, non-invasive tool for assessing muscle spasticity and monitoring BoNT-A response in children with CP. Its correlation with MAS supports physiological relevance and suggests NIRS may offer a more objective measure of spasticity. Larger studies are warranted to validate these findings and support clinical use.

Journal of NeuroEngineering and RehabilitationVol. 22(1)
University of British Columbia (CA), International Collaboration On Repair Discoveries (CA), BC Children's Hospital (CA)
Good health and well-being
Openalex Percentile: Top 37%
Cerebral Palsy and Movement Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.